MacroGenics, Inc. - Common Stock (NQ:MGNX)

2.440 +0.250 (+11.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles ↗

November 18, 2022

Via Benzinga

Gap, Palo Alto Networks And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 18, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

November 17, 2022

From MacroGenics, Inc.

Via GlobeNewswire

Why MacroGenics Stock Crushed the Market on Monday ↗

November 14, 2022

Positive momentum continues for the cancer specialist in the wake of its latest earnings report.

Via The Motley Fool

MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences ↗

November 14, 2022

BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16. BMO Capital analyst Etzer Darout upgraded the stock from Market Perform to Outperform. MacroGenics shares...

Via Benzinga

MacroGenics (MGNX) Q3 2022 Earnings Call Transcript ↗

November 03, 2022

MGNX earnings call for the period ending September 30, 2022.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Macrogenics ↗

August 09, 2022

Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:

Via Benzinga

MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce ↗

August 09, 2022

Via Benzinga

360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 14, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Blue Star (NASDAQ: BSFC) Insiders Are Buying Stock ↗

November 11, 2022

One indicator of where a company’s stock might be going in the future can be understood by what insiders may be thinking of the Company’s current stock price and near-term future outlook. Insiders are...

Via Benzinga

Why MacroGenics Stock Popped Again Today ↗

November 07, 2022

Investors and analysts alike are getting more bullish on the company in the wake of its third-quarter results.

Via The Motley Fool

Why MacroGenics Stock Blasted Higher Today ↗

November 04, 2022

A quarter that was far better than expected gets investors excited about the biotech at the end of the week.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 04, 2022

Gainers

Via Benzinga

Macrogenics: Q2 Earnings Insights ↗

August 08, 2022

Macrogenics (NASDAQ:MGNX) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session ↗

November 04, 2022

Gainers

Via Benzinga

MacroGenics to Participate in Upcoming Investor Conferences

November 02, 2022

From MacroGenics, Inc.

Via GlobeNewswire

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

October 26, 2022

From MacroGenics, Inc.

Via GlobeNewswire

$7.5 Million Bet On Local Bounti? Check Out These 3 Penny Stocks Insiders Are Buying ↗

October 26, 2022

US crude oil futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

$1.8 Million Bet On MacroGenics? Check Out These 3 Penny Stocks Insiders Are Buying ↗

October 24, 2022

The Dow Jones traded higher by over 400 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 21, 2022

Gainers

Via Benzinga

Analyst Ratings for Macrogenics ↗

October 18, 2022

Over the past 3 months, 5 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates ↗

October 17, 2022

Via Benzinga

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗

October 24, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 17, 2022

Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million.

Via Benzinga

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

October 17, 2022

From Gilead Sciences, Inc.

Via Business Wire

This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe ↗

September 12, 2022

Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading.

Via Benzinga

Where Macrogenics Stands With Analysts ↗

August 29, 2022

Over the past 3 months, 6 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers ↗

August 29, 2022

Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.